Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.48 |
| ▸ | CDK4 | P11802 | 5/20 | 0.45 |
| ▸ | CCND1 | P24385 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | CCND3 | P30281 | 3/20 | 0.39 |
| ▸ | CCND2 | P30279 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915752 | 1.00 | BTK (0.48) | BTKCDK4CCND1CDK2ADRA2A | |
| SCHEMBL14916553 | 1.00 | BTK (0.48) | BTKCDK4CCND1CDK2ADRA2A | |
| SCHEMBL14915354 | 0.88 | BTK (0.42) | BTKCDK4CCND1CCND3CCND2 | |
| SCHEMBL1394175 | 0.87 | BTK (0.40) | BTKCDK4CCND1CCND3CCND2 | |
| SCHEMBL14934337 | 0.87 | BTK (0.41) | BTK | |
| SCHEMBL1393623 | 0.86 | BTK (0.42) | BTK | |
| SCHEMBL708026 | 0.86 | BTK (0.52) | BTKCDK4CCND1CCND3CCND2 | |
| SCHEMBL18778753 | 0.86 | BTK (0.45) | BTK | |
| SCHEMBL14915792 | 0.85 | CDK4 (0.45) | BTKCDK4CCND1CDK2CCND3 | |
| SCHEMBL14915902 | 0.85 | CDK4 (0.45) | BTKCDK4CCND1CDK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773639-B1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| EP-2773639-B1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9115152-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115152-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8946213-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946213-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2773639-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729072-B2 | Alkylated piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2014-05-20 | — | — | US | disclosed |
| US-8729072-B2 | Alkylated piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2014-05-20 | — | — | US | disclosed |
| WO-2013067277-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | BTK 1/4885CDK4 463/4885CCND1 1461/4885 |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | BTK 1/4885CDK4 747/4885CCND1 2545/4885 |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | BTK 1/4885CDK4 463/4885CCND1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.